KRAS and non-small cell lung carcinoma: Moreover, our research uncovered a mechanism by which KRAS mutants foster resistance to chemotherapy in NSCLC cells by hijacking ALKBH5 PTM–mediated DNA damage response pathways (Figure 8F).